Parexel’s Near-Term Greenhouse Gas Reduction Targets Validated by Science Based Target Initiative (SBTi)
DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the...
Clinical Trial
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology...
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1...
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to...
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing
Exclusive licensing of 10 invention patents and patent applications surrounding gas sensor and medical devicesAll-stock licensing structure aligns the licensor's...
Xtant Medical Announces Closing of $5.0 Million Private Placement
BELGRADE, MT / ACCESSWIRE / August 9, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company...
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month – Created by a World-Class Pharmaceutical Research & Development Team
TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its...
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on...
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or...
Celly Nutrition Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month – Created by a World-Class Pharmaceutical Research & Development Team
Vancouver, British Columbia--(Newsfile Corp. - August 9, 2024) - Celly Nutrition Corp. ("Celly Nu" or the "Company"), which is backed...
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
- Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / August 8, 2024...
Avinger Reports Second Quarter 2024 Results
Implements Lower Operating Cost Profile, Readying OCT-Guided Coronary Device for IDE Submission REDWOOD CITY, CA / ACCESSWIRE / August 8,...
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...
Monogram Technologies Submits 510(k) Application for mBôs TKA System Clearance
Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive ReviewFDA Decision is...
Xtant Medical Announces $5.0 Million Private Placement
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company...
Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%
BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology...
NanoViricides Provides an Update on Its Clinical Program and Strategy – NV-387 Could be As Revolutionary as Antibiotics
SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallySARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE)...
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome...
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its...